Pediatric antiphospholipid syndrome: clinical features and therapeutic interventions in a single center retrospective case series

Jacqueline A. Madison1,2, Kelsey Gockman2, Claire Hoy2, Ajay Tambralli1,2, Yu Zuo2 and Jason S. Knight2

Abstract

Background/purpose: Pediatric antiphospholipid syndrome (APS) is a thromboinflammatory disease characterized by the presence of circulating antiphospholipid antibodies and either thrombotic events or pregnancy morbidity. The objective of this study was to review a large institution’s experience to better understand the characteristics of children with APS.

Methods: We conducted a retrospective review of pediatric APS at a tertiary referral center. The electronic medical record system was queried from 2000 through 2019, and 21 cases were included based on meeting the revised Sapporo Classification criteria by age 18 or younger. Comparisons between primary and secondary APS patients were made with two-tailed t-tests.

Results: Twenty-one patients were included with a median age at diagnosis of 16 years and median follow-up of 5.8 years. Secondary APS was slightly more common than primary APS (11 vs. 10 cases) and was primarily diagnosed in the context of systemic lupus erythematosus. Two thirds of patients (67%) also had “non-criteria” manifestations of APS including thrombocytopenia, autoimmune hemolytic anemia, and livedo reticularis/racemosa. Almost half of patients (43%) had recurrent thrombosis, typically when patients were subtherapeutic or non-adherent with anticoagulation. Damage Index in Patients with Thrombotic APS (DIAPS) scores indicated a chronic burden of disease in both primary and secondary APS patients.

Conclusion: This case series of pediatric APS provides important context regarding disease phenotypes displayed by children with APS. High prevalence of non-criteria clinical manifestations highlights the need to consider these characteristics when developing pediatric-specific classification criteria and when considering this relatively rare diagnosis in pediatric practice.

Keywords: Pediatrics, Antiphospholipid syndrome, Antiphospholipid antibodies, Thrombosis, Systemic lupus erythematosus, Damage Index (DIAPS), Non-criteria manifestations, Anti-phosphatidylserine/prothrombin

Background

Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by thrombotic events and/or pregnancy morbidity in the setting of persistently positive antiphospholipid antibodies (aPL). In adults, the Sapporo criteria (first developed in 1999 and revised in 2006) are used to formally classify APS for research purposes. These criteria require the presence of at least one clinical event (venous, arterial, or small
vessel thrombosis, or pregnancy-related morbidity) and the durable presence over at least 12 weeks of at least one laboratory feature: positive lupus anticoagulant (a functional assay that screens for aPL), antiphospholipid IgG or IgM in medium or high titer (>40 GPL/MPL or titer > 99th percentile), or anti-beta-2 glycoprotein I (β2GPI) IgG or IgM (titer > 99th percentile) [1]. There are no pediatric-specific criteria. Studies have shown that up to 25% of otherwise healthy children may have low levels of aPL, which may be transient and related to the developing immune system’s response to antigens, whether infectious or nutritional [2]. The concept of pediatric APS has generally been applied to children age 18 and younger, although other cut-offs including age 16 and 21 have also been used [3]. There is an ongoing effort to develop new APS classification criteria, including criteria specific for pediatric patients with APS [4].

The largest pediatric cohort described to date consists of an international registry of 121 patients diagnosed with APS before age 18, while the largest case series of North American pediatric APS patients included 17 children diagnosed at age 18 and younger [5, 6]. There have been a few other retrospective case series that are small in number but add to the characterization of this disease [7–11]. A consistent theme of these series is the presence of non-criteria manifestations: non-thrombotic clinical features not included in the updated Sapporo criteria such as livedo reticularis or racemosa, persistent thrombocytopenia, autoimmune hemolytic anemia, choreiform movements, white matter changes, cardiac valve abnormalities, and more [2, 6, 12, 13]. A task force on APS clinical features developed evidence-based recommendations for future criteria to include APS nephropathy, heart valve lesions, thrombocytopenia, livedo reticularis, chorea, and longitudinal myelitis [14]. There are few data in pediatric patients regarding non-criteria lab tests, such as anti-phosphatidylserine/prothrombin (anti-PS/PT) antibodies, a class of antibodies regularly associated with lupus anticoagulant positivity and thrombotic events [15–17].

Beyond challenges in diagnosis and characterization of pediatric APS, little is known about organ damage accumulated over time. Recently, the disease-specific Damage Index in Patients with Thrombotic APS (DIAPS) has been proposed to assess for damage accrual, although it has yet to be applied to a pediatric population [18, 19]. The objective of this study was to gather additional information about clinical characteristics, laboratory aPL positivity over time, treatments employed, thrombotic outcomes, and damage accrual in pursuit of enabling a more personalized and proactive approach to the care of children with APS.

Methods

Cohort identification and analysis

The University of Michigan IRB approved this study (HUM00161442). The electronic medical record system of Michigan Medicine was queried for patients aged 21 and younger with a diagnosis of APS from 2000 through 2019. Fifty cases were evaluated further, and 21 were ultimately included in this study. Excluded cases failed to meet the revised Sapporo Classification criteria by age 18 or younger. Of the 29 excluded cases (19 female and 10 male; 20 White or Caucasian, 7 Black or African-American, 1 Hispanic, and 1 Asian-American), 8 (28%) were excluded due to age over 18 at the time of meeting criteria (typically age of thrombotic event), and the remainder were excluded due to failing to meet the classification criteria at any point: 5 (17%) due to lack of laboratory criteria, 5 (17%) due to lack of clinical criteria, and 11 (38%) with neither laboratory nor clinical criteria (for example, a patient with a family history of APS in the electronic medical record system). Included cases were assessed for clinical and laboratory features, therapeutic management, and outcome data. Disease manifestations were identified by searching notes and imaging reports. One included case did not strictly meet Sapporo Classification criteria as the patient was treated aggressively with plasmapheresis and rituximab with resolution of traditional aPL tests by the time they were repeated six months later; this patient did, however, have durably positive non-criteria aPL (anti-PS/PT). There were no cases of neonatal APS or definite catastrophic APS (CAPS) identified in this cohort.

Antiphospholipid antibody measurements

Prior to 2015, aPL levels (anti-β2GPI and anticardiolipin) were measured at Michigan Medicine by Werfen QUANTA Lite® ELISA (maximum = 150). Since 2015, aPL have been quantified via a multiplex assay using the BioPlex 2200 System (maximum = 112). Neither the Werfen nor BioPlex assays utilize biotin-streptavidin reagents and thus should not be confounded by patient biotin levels or exogenous biotin use. A few laboratory test results were obtained from outside laboratories for which we do not know the details regarding the specific tests used. The lupus anticoagulant panel done at Michigan Medicine includes prothrombin time (reference range 9.4 – 12.2 s) with INR, partial thromboplastin time (reference range 21.0–29.0 s), dilute Russell’s viper venom test (DRVVT, reference range < 44.0 s), DRVVT ratio (reference range < 1.3), and hexagonal phospholipid neutralization (reference range less than or equal to 6.0 s). The phosphatidylserine/prothrombin antibody IgG and IgM panel is an ELISA (Werfen) with a reference range of negative at less than or equal to 30.0 units, borderline
over time, and positives are reported as abnormal accord-
ondary APS groups.

The demographics and disease features of all of the pedi-
ritic APS patients identified are detailed in Table 1. The
All met APS classification criteria by age 18 or younger.
Within this cohort, there were 10 and 11 patients with
primary and secondary APS, respectively. Among
patients with secondary APS and a concomitant rheu-
matic disease, most (9 or 82%) had a diagnosis of sys-
temic lupus erythematosus (SLE), and there was 1 patient
with ulcerative colitis and microscopic polyangiitis.

Within this cohort, there were 10 and 11 patients with
thrombotic APS, and positives are reported as abnormal accord-
ing to reference values at the time of testing. Anti-Sm and
anti-chromatin testing is via an extractable nuclear anti-
body panel for which the test methodology is a multiplex
flow immunoassay.

Damage Index in Patients with Thrombotic APS (DIAPS)
This scoring system has recently been proposed to assess
the accumulation of damage related to APS. The DIAPS
adds APS-specific items to others taken from the SLICC/
ACR Damage Index (SDI) for a total of 37 items: 22 from
the SDI plus 15 new items [19]. The score is a simple
summation of each output item. Severe damage has been
suggested as a DIAPS score of 3 or more [20]. DIAPS has
previously been used in patients with both primary APS
and APS secondary to SLE, and different patterns in the
kinetics of damage accumulation were identified in each
group [21].

Statistical analysis
Comparisons between primary and secondary APS
groups were analyzed via two-tailed t tests using Graph-
Pad software. Significance was defined as \( p < 0.05 \).

Results
Patient characteristics and clinical manifestations
Over a 20-year period, a total of 21 cases were identified.
Most patients in the cohort (95%) had a thrombotic
event though one 18-year-old secondary APS patient
was diagnosed with obstetric manifestations. Among
those with thrombotic APS, most had venous thrombotic
events (62%), while about a quarter had an arterial (29%)
or small-vessel event (24%). More arterial events were
seen in patients with secondary APS (5 compared to 1).
Arterial events in this series included stroke, myocardial
infarction, and other infarctions including those involv-
ing spleen and kidney. None of the patients in this cohort
were diagnosed with CAPS. Regarding non-criteria man-
difestations, there were no significant differences between
the primary and secondary APS groups. In our cohort,
over half of patients (52%) had persistent thrombocyto-
penia (<100,000/µl) at some point in their disease course.
Autoimmune hemolytic anemia was also common, noted
in 43% of patients. Livedo reticularis or racemosa was
seen in 24% of patients. Other manifestations are detailed
in Table 1.

Laboratory manifestations
In considering the laboratory manifestations of APS, we
evaluated the persistent positivity of typical aPL. Over at
least 12 weeks, 64% of our cohort were positive for anti-
\( \beta_2 \)GPI antibodies, 81% for anticardiolipin antibodies, and
52% for lupus anticoagulant. It should be noted that some
patients did not have repeat lupus anticoagulant testing
performed. Notes indicate that some providers may have
avoided testing due to concomitant use of heparin prod-
ucts which may lead to challenges in the interpretation
of the lupus anticoagulant assay depending on the assay,
heparin formulation, and anti-factor Xa effect achieved.
There were no statistically significant differences between
the primary and secondary APS groups with regards to
positivity of aPL. About half of the patients in the cohort
(10 total, 48%) were triple positive for all three aPL tests.
We also evaluated positivity of anticardiolipin and anti-
\( \beta_2 \)GPI over time (Fig. 1). A variety of patterns were noted:
continued positivity, increases in titer, and decreases
in titer (some below the threshold of positivity), which
could be either transient or persistent. There did not
appear to be notable differences in patterns displayed
among patients with primary versus secondary APS or
among those with different types of thrombosis (venous,
arterial, or small vessel). It did appear that IgG aPL were
more likely to be durably positive as compared with IgM
aPL, though we cannot draw definite conclusions given
our small sample size. There was also no clear relation-
ship between which patients were on hydroxychloro-
quione and those whose antibody titers decreased over
time (data not shown).

In two patients (one each in the primary and second-
ary APS groups), there was positive testing for anti-PS/
PT antibodies; we did not observe any negative tests in the cohort. In the patient with primary APS, the anti-PS/PT remained durably positive, even when anticardiolipin and anti-β2GPI antibodies became negative. Lupus anticoagulant was not tested regularly in this patient due to long-term use of low-molecular-weight heparin. We also tracked autoantibodies seen frequently in lupus; antinuclear antibodies (ANA), anti-double-stranded-DNA antibodies, and anti-chromatin antibodies were significantly more common in the secondary APS group and only rarely positive in the primary APS group (Table 1). Anti-Sm was detected only in the secondary APS group.

**Treatments**

All patients were treated with some form of antiplatelet or anticoagulant therapy. Only one patient was treated with aspirin alone for the duration of follow-up of this study. As seen in Fig. 2, significantly more patients

### Table 1: Demographics and clinical manifestations of pediatric APS patients

|                      | All APS  
 | (n = 21) | Primary APS (n = 10) | Secondary APS (n = 11) | p valuea |
|----------------------|-----------------|---------------------|------------------------|----------|
| **Median Age at Diagnosis** | 16 (8–18) | 16 (12–18) | 16 (8–18) | 0.42 |
| **Sex**              |               |                     |                        |          |
| Female               | 16 (76%)      | 8 (80%)             | 8 (73%)                | 0.70     |
| Male                 | 5 (24%)       | 2 (20%)             | 3 (27%)                | 0.70     |
| **Race/Ethnicity**   |               |                     |                        |          |
| White or Caucasian   | 17 (81%)      | 7 (70%)             | 10 (91%)               | 0.23     |
| Black or African-American | 3 (14%)  | 2 (20%)             | 1 (9%)                 | 0.49     |
| Hispanic             | 1 (5%)        | 1 (10%)             | 0 (0%)                 | 0.29     |
| **Clinical Manifestations** |         |                     |                        |          |
| Obstetric            | 1 (5%)        | 0 (0%)              | 1 (9%)                 | 0.34     |
| Thrombotic           | 20 (95%)      | 10 (100%)           | 10 (91%)               | 0.34     |
| Venous               | 13 (62%)      | 8 (80%)             | 5 (45%)                | 0.11     |
| Arterial             | 6 (29%)       | 1 (10%)             | 5 (45%)                | 0.079    |
| Small vessel         | 5 (24%)       | 3 (30%)             | 2 (18%)                | 0.54     |
| Catastrophic APS     | 0 (0%)        | 0 (0%)              | 0 (0%)                 |          |
| **Non-criteria Manifestations** |          |                     |                        |          |
| Thrombocytopenia     | 11 (52%)      | 6 (60%)             | 6 (55%)                | 0.52     |
| AIHA                 | 9 (43%)       | 4 (40%)             | 6 (55%)                | 0.80     |
| Livedo               | 5 (24%)       | 3 (30%)             | 2 (18%)                | 0.54     |
| White matter lesions | 3 (14%)       | 1 (10%)             | 2 (18%)                | 0.60     |
| Seizure              | 3 (14%)       | 1 (10%)             | 2 (18%)                | 0.60     |
| APS nephropathy      | 2 (10%)       | 1 (10%)             | 1 (9%)                 | 0.95     |
| Skin ulcer           | 1 (5%)        | 0 (0%)              | 1 (9%)                 | 0.34     |
| Valve abnormality    | 1 (5%)        | 1 (10%)             | 0 (0%)                 | 0.29     |
| Cognitive changes    | 1 (5%)        | 0 (0%)              | 1 (9%)                 | 0.34     |
| MS-like features     | 1 (5%)        | 0 (0%)              | 1 (9%)                 | 0.34     |
| **Laboratory Manifestations** |         |                     |                        |          |
| Anti-β2-glycoprotein I | 14 (64%)   | 8 (80%)             | 7 (64%)                | 0.42     |
| Anti-cardiolipin     | 17 (81%)      | 9 (90%)             | 7 (64%)                | 0.16     |
| Lupus anticoagulant  | 11 (52%)      | 6 (60%)             | 6 (55%)                | 0.80     |
| Triple positive      | 10 (48%)      | 6 (60%)             | 4 (36%)                | 0.29     |
| ANA                  | 9 (43%)       | 0 (0%)              | 9 (82%)                | 0.00020  |
| Anti-double-stranded DNA | 10 (48%) | 1 (10%)             | 9 (82%)                | 0.0013   |
| Anti-chromatin       | 8 (38%)       | 1 (10%)             | 7 (64%)                | 0.014    |
| Anti-Sm              | 3 (14%)       | 0 (0%)              | 3 (27%)                | 0.082    |
| Recurrent Events     | 9 (43%)       | 4 (40%)             | 5 (45%)                | 0.81     |

*Comparing primary and secondary APS by unpaired t-test or Chi-squared test

AIHA Autoimmune hemolytic anemia, MS Multiple Sclerosis
with secondary APS as compared with primary APS were treated with aspirin \((p = 0.04)\). A small number of patients in both groups were treated with a direct oral anticoagulant or with fondaparinux. Not surprisingly, significantly more secondary APS patients were treated with hydroxychloroquine \((p = 0.02)\) and with an immunomodulatory agent \((p = 0.02)\). Primary APS patients who received immunomodulatory therapy (3 total) received some combination of rituximab (3), glucocorticoids (2), eculizumab (1), and IVIG (1). In the secondary APS group, a wider variety of immunomodulatory agents were prescribed for 9 patients: glucocorticoids (6), belimumab (3), mycophenolate mofetil (3), azathioprine (3), cyclophosphamide (2), methotrexate (2), quinacrine (2), rituximab (2), IVIG (1), tocilizumab (1), and abatacept (1). A small number of patients in both primary and secondary APS groups were treated with plasmapheresis or a statin.

**Outcomes**

Recurrence of thrombotic events was relatively common in both primary (40%) and secondary (45%) APS groups (Table 1). Although some had the same type of thrombotic event with their recurrence (such as a second
episode of venous thrombosis), this was not always the case (Table 2). Almost all the patients with a recurrent event were either not prescribed therapeutic anticoagulation (aspirin alone) or were subtherapeutic on their anticoagulation, in some cases attributed to chance and in others noncompliance. One recurrent event occurred while a patient was on a direct oral anticoagulant (DOAC) albeit with questionable adherence, and a second occurred about a week after a patient stopped taking a DOAC due to hospitalization. Another recurrent episode of thrombosis occurred while a patient was receiving the combination of aspirin and fondaparinux. To quantify damage accrued over time, the DIAPS was utilized based on the clinical status at the patient’s most recent contact with their physician (Fig. 3). In both primary and secondary APS groups, damage measured via the DIAPS demonstrated similar median scores in the two groups (1.5 and 1.2, respectively). A total of 3 patients had a score of 3 or higher.

**Discussion**

This case series adds to the relatively limited body of knowledge about children who develop APS and provides some important information that could inspire new ideas about how to best diagnose, manage, and research pediatric APS. For example, this series again highlights the burden of non-criteria clinical manifestations in the pediatric population and reinforces the need for pediatric-specific classification criteria. Patients who present with features such as the so-called Evans Syndrome (autoimmune hemolytic anemia and thrombocytopenia), for example, likely warrant testing for APS. Of note, the 15th International Congress on Antiphospholipid Antibodies Task Force on Pediatric Antiphospholipid Syndrome published a report that highlighted the different characteristics seen in pediatric APS and also underlined the importance of large, age-stratified studies to better identify risk for thrombotic events and to test the hypothesis that adult criteria may not be as useful in children [22]. Our data also confirm that testing for ANA is not a good screening test for APS because it was only positive in 43% of all patients with APS and none of the patients with primary APS. If a diagnosis of APS is being considered, then screening should be with aPL rather than relying on ANA as a surrogate marker.

There are no pediatric-specific laboratory cut-offs for aPL with percentiles based on healthy adults. Centers may consider determining an appropriate cut-off value for positive or negative aPL results based on pediatric controls. In our series, anti-PS/PT was tested in just two patients and was positive in both. One patient presented with thrombotic microangiopathy, and their other aPL either became negative after the use of plasmapheresis and rituximab or, in the case of lupus anticoagulant, could not be relied upon because of the use of heparin products. Hence, anti-PS/PT could potentially provide useful diagnostic information in cases in which APS is strongly suspected but unable to be confirmed with
current criteria lab testing. Interestingly, there have been two case reports of pediatric APS patients with positive anti-PS/PT and thrombotic microangiopathy [23, 24]. One other series of APS patients evaluating anti-PS/PT included pediatric patients and showed a significant association between test positivity and APS; it could even be used to diagnose clinical cases when other aPL were negative [25]. Further research in this area seems warranted.

Our series adds to what is known about recurrent events in pediatric APS patients. Recurrence was common in our series, involving nearly half of patients both in primary and secondary APS groups. That nearly all events occurred while a patient was not on therapeutic

| Pt | Age first event (years) | APS type | Triple + aPL | Initial treatment | Time to recurrence (months) | Recurrent event | AC prescribed at time of recurrence | Adherence to AC treatment |
|----|-------------------------|----------|-------------|------------------|-----------------------------|-----------------|------------------------------------|--------------------------|
| 5  | 14                      | 2°, Thr  | Yes         | Splenic infarction | LDA                         | 7.6             | Renal TMA                         | LDA                     | Yes                      |
| 8  | 17                      | 2°, Thr  | Yes         | Myocardial infarction | Fondaparinux and LDA | 80.5            | Cardiac thrombus                   | LDA; apixaban recently discontinued | Yes                      |
| 11 | 16                      | 1°, Thr  | Yes         | PE, lower extremity DVT | Warfarin                  | 59.0            | Lower extremity DVT               | Warfarin                | No (loss of health insurance) |
| 13 | 16                      | 2°, Thr  | No          | Lower extremity DVT | Warfarin (planned for 3 months) | 19.4            | Lower extremity DVT               | None                    | -                        |
| 14 | 18                      | 2°, Obs  | No          | HELLP, Pre-eclampsia, thrombotic vasculopathy of placenta and skin | LMWH – prophylactic dose | 4.6             | Early pregnancy loss               | LMWH – prophylactic dose | Yes                      |
| 16 | 10                      | 2°, Thr  | No          | CVA, renal infarction | LMWH                  | 23.4            | CVA                              | LMWH                    | No (physician reported) |
| 18 | 12                      | 1°, Thr  | Yes         | Liver lesions with small-vessel thrombotic vasculopathy | LMWH | 3.0             | PE                              | LMWH                    | No (family reported) |
| 19 | 15                      | 1°, Thr  | Yes         | Lower extremity DVT | LMWH transitioned to warfarin | 36.8            | Portal vein thrombosis            | Warfarin                | No (physician reported) |
| 20 | 17                      | 1°, Thr  | No          | Lower extremity DVT | LMWH                  | 2.0             | PE                              | None (suspected medication interaction on LMWH) | - |
|    |                         |          |             |                  |                  | 2.9             | PE                              | Warfarin (sub-therapeutic) transitioning to LMWH | Yes |
|    |                         |          |             |                  |                  | 4.0             | PE                              | LMWH                    | No (physician reported) |
|    |                         |          |             |                  |                  | 11.6            | PE with secondary pulmonary infarction | Fondaparinux and LDA | Yes |

Pt: Patient number, AC: Anticoagulation, 1°: Primary APS, 2°: Secondary APS, Obs: Obstetric, Thr: Thrombotic, LDA: Low dose aspirin, TMA: Thrombotic Microangiopathy, PE: Pulmonary embolism, DVT: Deep Vein Thrombosis, HELLP: Hemolysis, Elevated Liver enzymes, Low Platelet count syndrome, LMWH: Low molecular weight heparin (enoxaparin), CVA: Cerebrovascular accident, *2000-2004, **2005-2009, ***2010-2014, ****2015-2020
anticoagulation underscores the vital importance of APS patients being prescribed and staying on therapeutic levels of anticoagulation. A similar finding was seen in another pediatric case series in which there was a recurrence rate of 59%, with 80% of those events occurring when patients were not receiving therapeutic levels of anticoagulation [5]. The large pediatric APS registry had a lower recurrence rate of 19% [6], and another series of 28 children had a rate of 29% [10]. In review of the patients in our series, some physicians opted to stop anticoagulation when aPL became negative. Two such patients (patients 8 and 20, seen in Table 2 and Fig. 1) had recurrences despite aPL levels that dropped below the threshold of lab positivity over time. Although there has not been a pediatric-specific study on this topic, one study in adults found that by five years of follow-up, recurrent thrombotic events occurred in almost half of APS patients whose aPL became negative and in whom anticoagulation had been discontinued [26].

Therapeutic approaches in pediatric APS are heterogeneous and largely based on adult studies, anecdotal evidence in children, and clinicians’ experience. The largest evidence-based recommendations come from an initiative in Europe, in which treatment guidelines largely rely on descriptive studies and expert opinion; the group recommends consideration of antiplatelet agents in addition to hydroxychloroquine in patients with SLE and positive aPL; anticoagulation for venous thrombotic events when related to aPL; long-term anticoagulation in the setting of venous thrombosis and persistent aPL positivity; adequate long-term anticoagulation possibly in combination with antiaggregant therapy in the setting of arterial thrombosis and persistent aPL positivity; and consideration of elevated INR goals or alternative therapies with recurrent thrombotic events and persistent aPL positivity [27]. In our study, when evaluating the types of therapies employed, heparinoids and vitamin K antagonists (VKAs) were used most frequently, as expected. DOACs were used for some patients (4 total), most often when they became older in an effort to improve compliance. Two of the four patients had recurrent events. One recurrence occurred when the medication had recently been stopped about a week prior to the recurrence and one occurred when the patient was reported to be skipping doses (patients 8 and 13 in Table 2). One might postulate that the relatively short half-life of DOACs compared to VKAs could make patients on DOACs at particular risk for recurrence if they are not strictly adherent to their medications. Of note, there is one published case of a pediatric APS patient without recurrence on a DOAC with five months of follow-up [7], but there are few other data on this topic. Our case series found a relatively low rate of aspirin use, especially in primary APS. The primary APS group also had low utilization of hydroxychloroquine, which has been studied as a successful adjunctive therapy to anticoagulation in small studies of adult primary APS patients [28, 29] in addition to recommendations for its use in all aPL-positive patients with lupus by the 14th International Congress APS Treatment Trends Taskforce [30]. The potential use of hydroxychloroquine in pediatric APS patients underscores the potential benefits of collaboration between hematology and rheumatology, especially in refractory cases.

Our study was limited by its retrospective nature. As such, not every manifestation of interest was tested for in every patient; as an example, an echocardiogram was not performed in every patient, and as such, valve disease may have been present and missed. Some of these patients were managed by rheumatologists and others primarily by hematologists. The work-up and management were likely different due in part to the specific training and possible biases of different providers’ specialties. These patients were also collected over the course of 20 years, and the knowledge about APS has improved over that time.

The use of the DIAPS to assess for long-standing damage does show that even in pediatric APS patients, substantial morbidity can accumulate. Though some pediatric APS patients do well without acquiring new problems beyond the initial event that led to their diagnosis, others accrued significant damage over time. Although the median scores of 1.5 and 1.2 in primary and secondary pediatric APS patients, respectively, are lower than most of those previously reported in adults [26],
they still indicate a growing burden of disease in a young population. Within our cohort of 21 patients, 3 accumulated severe damage based on their DIAPS score. In previous studies of adults, the DIAPS correlates inversely with quality-of-life measures [26]. Elevated scores with distinct patterns have been shown in adults with primary APS, in which damage is an early event correlated with delay in diagnosis, and in APS with SLE, in which acquired damage occurs as an accumulation over time [21]. To our knowledge, this is the first application of the DIAPS to pediatric APS patients. It may continue to be employed when evaluating pediatric APS patients to add to our understanding of the serious long-term effects of this disease in children.

Conclusions
This case series provides additional information on certain features of pediatric APS, a relatively understudied and rare disease with significant morbidity. First, pediatric patients frequently exhibit non-criteria manifestations of APS, suggesting the need for pediatric-specific classification criteria and more widespread knowledge of these additional features when considering the diagnosis. The application of the DIAPS suggests that in some patients, there may be a significant burden of damage accrued over time. Recurrent thrombosis is common in nearly half of patients, and among those, subtherapeutic anticoagulation or anticoagulant medication non-adherence is almost universally identified. This finding emphasizes the challenges of effective anticoagulation in the pediatric population and highlights the importance of identifying other effective treatments in APS. Recurrent events occurred even when some patients’ aPL titers fell below positive thresholds, so this may not be a reliable indication as to when it might be safe to stop anticoagulation. With regards to lab testing for APS, anti-PS/PT could be considered as an additional aPL lab test in patients for whom clinical suspicion of APS is high. ANA may not be positive in APS, particularly primary APS, and so it should not be used as a screening test for APS in pediatric patients. The clinical characteristics, laboratory features, and outcomes described in this case series add to what is known about pediatric APS and may suggest areas requiring further study.

Acknowledgements
Not applicable.

Authors’ contributions
JAM and JSK conceived the study. JAM, CH, KG, AT, and YZ collected and analyzed data. All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be submitted.

Funding
JAM and AT were partially supported by the VA Ann Arbor Healthcare System. YZ was supported by career development awards from the Rheumatology Research Foundation and Arthritis National Research Foundation. JSK was supported by awards from the NIH (R01HL134846), Burroughs Wellcome Fund, Lupus Research Alliance, and Rheumatology Research Foundation.

Availability of data and materials
The datasets generated and analyzed during the current study are not publicly available because the sharing could compromise individual privacy, but deidentified datasets are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
The University of Michigan IRB approved this study (HUM00161442).

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Pediatrics, Division of Pediatric Rheumatology, University of Michigan, Ann Arbor, MI, USA. 2 Department of Internal Medicine, Division of Rheumatology, University of Michigan, 1150 West Medical Center Drive, Ann Arbor, MI 48109, USA.

Received: 29 October 2021 Accepted: 12 February 2022
Published online: 23 February 2022

References
1. Miyakis S, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295–306.
2. Rumsey DG, Myones B, Massicotte P. Diagnosis and treatment of antiphospholipid syndrome in childhood. A review. Blood Cells Mol Dis. 2017;67:34–40.
3. Aguilar CL, et al. Pediatric antiphospholipid syndrome. Curr Rheumatol Rep. 2015;17(4):27.
4. Barbhaiya M, et al. Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria. Arthritis Care Res. 2021;73(10):1490–501.
5. Nagiwa Rao AA, et al. A retrospective review of pediatric antiphospholipid syndrome and thrombosis outcomes. Blood Coagul Fibrinolysis. 2017;28(3):205–10.
6. Avci T, et al. Pediatric antiphospholipid syndrome: clinical and immunologic features of 121 patients in an international registry. Pediatrics. 2008;122(5):e1100–7.
7. Ma J, et al. Clinical characteristics and thrombosis outcomes of paediatric antiphospholipid syndrome: analysis of 58 patients. Clin Rheumatol. 2018;37(5):1295–303.
8. Tavil B, et al. Antiphospholipid antibodies in Turkish children with thrombosis. Blood Coagul Fibrinolysis. 2007;18(4):347–52.
9. Zamora-Ustaran A, et al. Antiphospholipid syndrome in Mexican children. Isr Med Assoc J. 2012;14(5):286–9.
10. Berkun Y, et al. Antiphospholipid syndrome and recurrent thrombosis in children. Arthritis Rheum. 2006;55(6):850–5.
11. Ravelli A, Martini A. Antiphospholipid antibody syndrome in pediatric patients. Rheum Dis Clin North Am. 1997;23(3):657–76.
12. Wincup C, Ioannou Y. The Differences Between Childhood and Adult Onset Antiphospholipid Syndrome. Front Pediatr. 2018;6:362.
13. Meroni PL, Argolini LM, Pontikaki I. What is known about pediatric antiphospholipid syndrome? Expert Rev Hematol. 2016;9(10):977–85.
14. Abreu MM, et al. The relevance of "non-criteria" clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. Autoimmun Rev. 2015;14(3):401–14.
15. Shi H, et al. Antiphosphatidylserine/prothrombin antibodies (aPS/PT) as potential diagnostic markers and risk predictors of venous thrombosis and obstetric complications in antiphospholipid syndrome. Clin Chem Lab Med. 2018;56(4):614–24.
16. Sciascia S, et al. Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review Thromb Haemost. 2014;111(2):354–64.
17. Korenatsu S, et al. Central retinal vein occlusion in a pediatric patient with SLE and antiphospholipid antibodies without anti-cardiolipin or anti-beta2 glycoprotein I antibodies. BMC Pediatr. 2014;14:116.
18. Amigo MC, et al. Development and initial validation of a damage index (DIAPS) in patients with thrombotic antiphospholipid syndrome (APS). Lupus. 2015;24(9):927–34.
19. Alba P, et al. Organ Damage and Quality of Life in Antiphospholipid Syndrome. Curr Rheumatol Rep. 2016;18(2):7.
20. Medina G, et al. Damage index for antiphospholipid syndrome during long term follow-up: Correlation between organ damage accrual and quality of life. Lupus. 2021;30(1):96–102.
21. Torricelli AK, et al. Antiphospholipid syndrome damage index (DIAPS): distinct long-term kinetic in primary antiphospholipid syndrome and antiphospholipid syndrome related to systemic lupus erythematosus. Lupus. 2020;29(3):256–62.
22. Soybilgic A, et al. 15th International Congress on Antiphospholipid Antibodies Task Force on Pediatric Antiphospholipid Syndrome Report. New York: Springer International Publishing; 2017. p. 291–306.
23. Noda S, et al. Thrombotic microangiopathy due to multiple autoantibodies related to antiphospholipid syndrome. Pediatr Nephrol. 2012;27(4):681–5.
24. Senda Y, et al. Microangiopathic antiphospholipid antibody syndrome due to anti-phosphatidylserine/prothrombin complex IgM antibody. Pediatr Int. 2017;59(3):378–80.
25. Khoegheer H, et al. Antiphosphatidylserine antibodies as diagnostic indicators of antiphospholipid syndrome. Lupus. 2015;24(2):186–90.
26. Medina G, et al. Antiphospholipid antibodies disappearance in primary antiphospholipid syndrome: Thrombosis recurrence. Autoimmun Rev. 2017;16(4):352–4.
27. Groot N, et al. European evidence-based recommendations for diagnosis and treatment of paediatric antiphospholipid syndrome: the SHARE initiative. Ann Rheum Dis. 2017;76(10):1637–41.
28. Schmidt-Tanguy A, et al. Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients. J Thromb Haemost. 2013;11(10):1927–9.
29. Nuri E, et al. Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome. Immunol Res. 2017;65(1):17–24.
30. Erkan D, et al. 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev. 2014;13(6):685–96.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.